Literature DB >> 18706269

Treatment of diffuse large B-cell lymphoma in the elderly: strategies integrating oncogeriatric themes.

Pieternella J Lugtenburg1, Pieter Sonneveld.   

Abstract

With an increasingly aged population, many patients will present with diffuse large B-cell lymphoma in their 70s and 80s. Recently, several randomized studies have confirmed the benefit of rituximab in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) and showed a substantial improvement in the outcome of fit elderly patients. This article reviews the efficacy and toxicity of the current treatment regimens applied for the treatment of diffuse large B-cell lymphoma in elderly patients and provides practical recommendations for the management of these patients.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18706269     DOI： 10.1007/s11912-008-0063-2

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  47 in total

1.  2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Authors:  Thomas J Smith; James Khatcheressian; Gary H Lyman; Howard Ozer; James O Armitage; Lodovico Balducci; Charles L Bennett; Scott B Cantor; Jeffrey Crawford; Scott J Cross; George Demetri; Christopher E Desch; Philip A Pizzo; Charles A Schiffer; Lee Schwartzberg; Mark R Somerfield; George Somlo; James C Wade; James L Wade; Rodger J Winn; Antoinette J Wozniak; Antonio C Wolff
Journal:  J Clin Oncol       Date:  2006-05-08       Impact factor: 44.544

2.  Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non-Hodgkin's lymphoma.

Authors:  Mayumi Mori; Kiyoshi Kitamura; Michihiko Masuda; Tomomitsu Hotta; Tamotsu Miyazaki; Akira B Miura; Hideaki Mizoguchi; Akira Shibata; Hidehiko Saito; Tamotsu Matsuda; Toru Masaoka; Mine Harada; Yoshiyuki Niho; Fumimaro Takaku
Journal:  Int J Hematol       Date:  2005-04       Impact factor: 2.490

3.  Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.

Authors:  P Feugier; A Van Hoof; C Sebban; P Solal-Celigny; R Bouabdallah; C Fermé; B Christian; E Lepage; H Tilly; F Morschhauser; P Gaulard; G Salles; A Bosly; C Gisselbrecht; F Reyes; B Coiffier
Journal:  J Clin Oncol       Date:  2005-05-02       Impact factor: 44.544

4.  Effect of age on the characteristics and clinical behavior of non-Hodgkin's lymphoma patients. The Non-Hodgkin's Lymphoma Classification Project.

Authors: 
Journal:  Ann Oncol       Date:  1997-10       Impact factor: 32.976

5.  Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).

Authors:  A Wunderlich; M Kloess; M Reiser; C Rudolph; L Truemper; S Bittner; H Schmalenberg; R Schmits; M Pfreundschuh; M Loeffler
Journal:  Ann Oncol       Date:  2003-06       Impact factor: 32.976

6.  Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim.

Authors:  Lodovico Balducci; Hafez Al-Halawani; Veena Charu; Jennifer Tam; Seta Shahin; Lyndah Dreiling; William B Ershler
Journal:  Oncologist       Date:  2007-12

Review 7.  Monoclonal antibodies for B-cell lymphomas: rituximab and beyond.

Authors:  Celeste Bello; Eduardo M Sotomayor
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2007

8.  A predictive model for aggressive non-Hodgkin's lymphoma.

Authors: 
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

9.  Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma.

Authors:  Gary H Lyman; David J Delgado
Journal:  Cancer       Date:  2003-12-01       Impact factor: 6.860

10.  Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.

Authors:  Michael Pfreundschuh; Lorenz Trümper; Marita Kloess; Rudolf Schmits; Alfred C Feller; Christian Rübe; Christian Rudolph; Marcel Reiser; Dieter K Hossfeld; Hartmut Eimermacher; Dirk Hasenclever; Norbert Schmitz; Markus Loeffler
Journal:  Blood       Date:  2004-03-11       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.